



**Consolidated Financial Statements for the Second Quarter Ended September 30, 2020
FY2021 (April 1, 2020 - September 30, 2020) [UNAUDITED]**

November 10, 2020

Company name:	Takara Bio Inc.
Stock exchange listings:	Tokyo Stock Exchange (1st section)
Code number:	4974
URL:	https://www.takara-bio.co.jp
Company representative:	Koichi Nakao, President
Contact:	Takuya Kakemi, General Manager of Corporate Management Division, Executive Officer Tel. (077) 565-6970
Scheduled date of quarterly statement filing:	November 12, 2020
Scheduled date of starting delivery of dividends:	—
Supplementary documents of the financial results:	Yes
Financial results information meeting:	Yes

Notes: 1. The accompanying financial statements have been prepared in accordance with accounting principles and practices generally accepted in Japan.
2. Amounts are rounded down to the nearest million yen.

1. Results for the six months ended September 30, 2020 (Apr. 1, 2020 – Sep. 30, 2020)

(1) Consolidated operating results

(Percentages indicate changes from the same period of the previous fiscal year.)

	Six months ended Sep. 30, 2020		Six months ended Sep. 30, 2019	
	(Millions of yen)	(%)	(Millions of yen)	(%)
Net sales	17,393	5.7	16,450	(5.3)
Operating profit	3,736	23.1	3,035	15.7
Ordinary profit	3,820	29.0	2,961	10.9
Net income (loss) attributable to owners of parent	2,274	9.6	2,075	20.6
Net income per share (in yen)	18.89		17.23	
Fully diluted net income per share (in yen)	—		—	
(Note) Comprehensive income	1,608	(36.0)	1,182	(39.2)

(2) Consolidated financial position

	As of Sep. 30, 2020	As of Mar. 31, 2019
	(Millions of yen)	(Millions of yen)
Total assets	77,343	75,009
Net assets	67,236	66,591
Equity ratio (%)	86.8	88.7
Net assets per share (in yen)	557.50	552.23
(Reference) Equity	67,131	66,496

2. Dividends

	Annual dividends per share in yen		
	Year ended Mar. 31, 2020	Year ending Mar. 31, 2021	Year ending Mar. 31, 2021 (Forecast)
First quarter end	—	—	—
Second quarter end	0.00	0.00	—
Third quarter end	—	—	—
Year end	8.00	—	9.00
Annual	8.00	—	9.00

(Note) Revision of dividend payment forecast since the most recently announced payment forecast: Yes

The original disclosure in Japanese was released on November 10, 2020 at 15:00 (GMT+8)

3. Forecast for the year ending March 31, 2021 (Apr. 1, 2020 – Mar. 31, 2021)

(Percentages indicated changes from the same period of the previous fiscal year.)

	Year ending Mar. 31, 2021	
	(Millions of yen)	(Millions of yen)
Net sales	40,800	18.0
Operating profit	8,000	27.5
Ordinary profit	8,100	27.6
Net income attributable to owners of the parent	5,000	30.9
Net income per share (in yen)	41.52	

(Note) Revision of financial forecast since the most recently announced payment forecast: Yes

※ Others

(1) Changes in subsidiaries during the six months ended September 30, 2020

(Changes in specified subsidiaries resulting in change of scope) : No

Newly included: – (Name)

Excluded: – (Name)

(2) Application of special accounting methods to the consolidated quarterly financial statements: No

(3) Changes in accounting policies, changes in accounting estimates, and retrospective restatement

1) Changes based on revisions of accounting standard: No

2) Changes other than ones based on revisions of accounting standard: No

3) Changes in accounting estimates: No

4) Restatement: No

(4) Number of outstanding shares (Common stock)

1) Number of outstanding shares at year end (Treasury stocks are included)

As of September 30, 2020 120,415,600

As of March 31, 2020 120,415,600

2) Number of treasury stocks at year end

As of September 30, 2020 –

As of March 31, 2020 –

3) Average number of outstanding shares

As of September 30, 2020 120,415,600

As of September 30, 2019 120,415,600

※ These financial statements are not subject to auditing.

※ Comment regarding appropriate use of earnings forecasts and other special notes

Forward-looking statements contained in this document are determined by the Takara Bio Company based on information currently available to the Company and include a number of uncertainties. Actual results could differ from these forecasts due to changes in conditions that occur in the future. For information regarding the above, please refer to 1. Qualitative Information for the six months ended September 30, 2020 (4) Qualitative Information Regarding Consolidated Forecasts, on page 2 of the attached document.

Contents of the attached document

1. Qualitative Information for the six months ended September 30, 2020.....	2
(1) Overview of Financial Results.....	2
(2) Overview of Financial Position.....	2
(3) Overview of Cash Flows.....	2
(4) Qualitative Information Regarding Consolidated Forecasts.....	2
2. Consolidated Quarterly Financial Statements and Primary Notes.....	3
(1) Consolidated Quarterly Balance Sheets.....	3
(2) Consolidated Quarterly Statements of Profit or Loss and Consolidated Quarterly Statements of Comprehensive Income.....	5
(Consolidated Quarterly Statements of Profit or Loss)	
(For the six months ended September 30, 2020)	5
(Consolidated Quarterly Statements of Comprehensive Income)	
(For the six months ended September 30, 2020)	6
(3) Consolidated Quarterly Statements of Cash Flows.....	7
(4) Notes to Consolidated Quarterly Financial Statements.....	8
(Notes on Premise of Going Concern)	8
(Notes in case of Changes in Marked Amount of Shareholders' Equity)	8
(Additional Information).....	8
(Segment Information).....	8
3. Supplementary Information	9
(1) Trends in Key Management Indicators.....	9
(2) Comparative Consolidated Statement of Profit or Loss	10
(3) Comparative Statement of Profit Relating to Consolidated Earnings Forecast.....	11

1. Qualitative Information for the six months ended September 30, 2020

(1) Overview of Financial Results

In the fiscal year under review, ended September 30, 2020, the global economy has continued to be uncertain due to the influence of the new Coronavirus disease (COVID-19) pandemic, the trade friction issue in the US and China, and Brexit, etc.

Against these circumstances, under our corporate philosophy of “Contributing to the health of humankind through the development of revolutionary biotechnologies such as gene therapy”, Takara Bio (the Company) is promoting the development of bio-drug discovery platform technologies through the businesses of research reagents and scientific instruments and CDMO business, aiming to become a drug discovery company and continuously creates new modalities in line with “Long-Term Management Plan FY2026” and “Medium-Term Management Plan FY2023”

As a result, overall net sales in the fiscal year under review, ended September 30, 2020 increased 5.7% year on year to ¥17,393 million, due to the contributions from sales for research reagents and contract services exceeding those of the same period of the previous fiscal year, despite the decrease in the Gene Therapy compared with the same period of the previous fiscal year. Cost of sales decreased 9.1% year on year to ¥5,565 million due to the change of sales composition by item and others, and an increase in production utilization rates, and gross profit increased 14.5% year on year to ¥11,827 million. Selling, general and administrative (SG&A) expenses increased 10.9% year on year to ¥8,090 million due to the increase in R&D expenses, and the Company recorded operating profit up 23.1% year on year to ¥3,736 million.

Accompanied with the increase in operating profit, ordinary profit increased 29.0% to ¥3,820 million, profit before income taxes and others increased 11.2% year on year to ¥3,281 million, and net income attributable to owners of parent increased 9.6% year on year to ¥2,274 million.

Segment information has been omitted since the reportable segments were changed to a single segment since the three months ended June 30, 2020. For details, please refer to “2. Consolidated Quarterly Financial Statements and Primary Notes (Segment Information)”.

(2) Overview of Financial Position

In the fiscal year under review, total assets were ¥77,343 million, an increase of ¥2,334 million compared with that at the end of the previous fiscal year. This primarily resulted from an increase in non-current assets of ¥3,849 million based on the acquisition of land and building for the new facility of Takara Bio USA, Inc..

In the fiscal year under review, total liabilities were ¥10,106 million, an increase of ¥1,688 million compared with that at the end of the previous fiscal year. This primarily resulted from an increase of ¥1,021 million in others for current liabilities.

In the fiscal year under review, total net assets stood at ¥67,236 million, an increase of ¥645 million compared with that at the end of the previous fiscal year. The main factor was an increase of ¥1,311 million in retained earnings and a decrease of ¥692 million in foreign currency translation adjustment due to the appreciation of the yen.

(3) Overview of Cash Flows

Net cash provided by operating activities was ¥5,553 million, up by ¥844 million compared with the same period of the previous fiscal year. This was mainly due to profit before income taxes and others of ¥3,281 million, depreciation and amortization of ¥1,631 million, cash inflow of ¥1,178 million from an increase in current liabilities, and cash outflow of ¥1,481 million from an increase in inventories.

Net cash provided by investing activities was ¥2,417 million, an increase of ¥133 million compared with the same period of the previous fiscal year. This was primarily due to ¥5,750 million in payments for purchase of property, plant and equipment and intangible assets, and ¥2,000 million in proceeds from sales and redemption of securities.

Net cash used in financing activities was ¥1,030 million, an increase ¥145 million compared with the same period of the previous fiscal year. This was primarily because of an increase of ¥961 million in cash dividends paid.

As a result of the above, balance of cash and cash equivalents at the end of second quarter of the current fiscal year, including the effect of exchange rate change on cash and cash equivalents, stood at ¥16,360 million, up by ¥1,897 million from the previous fiscal year-end.

(4) Qualitative Information Regarding Consolidated Forecasts

The Company has revised the financial forecast disclosed on August 4, 2020, and the dividend forecast. For details, refer to “Notice Regarding Forecast Revisions of Financial results and Dividend (Dividend Increase)” disclosed on November 10, 2020.

For comparison between revised forecast for consolidated results, previous period results, and previous forecast, refer to “Comparative Statement of Profit Relating to Consolidated Earnings Forecasts” on page 11.

2. Consolidated Quarterly Financial Statements and Primary Notes

(1) Consolidated Quarterly Balance Sheets

(Millions of yen)

	As of Mar. 31, 2020	As of Sep. 30, 2020
Assets		
Current assets		
Cash and deposits	18,266	18,627
Notes and accounts receivable-trade	9,102	8,448
Marketable securities	2,000	—
Merchandise and finished goods	4,511	4,829
Work in process	1,208	1,410
Raw materials and supplies	1,874	2,606
Other	1,479	1,005
Allowance for doubtful accounts	(56)	(56)
Total current assets	38,387	36,871
Non-current assets		
Property, plant and equipment		
Buildings and structures	16,478	15,349
Accumulated depreciation	(5,630)	(4,746)
Buildings and structures, net	10,847	10,602
Machinery, equipment and vehicles	6,705	6,895
Accumulated depreciation	(3,353)	(3,505)
Machinery, equipment and vehicles, net	3,352	3,389
Tools, furniture and fixtures	7,912	7,783
Accumulated depreciation	(5,217)	(5,126)
Tools, furniture and fixtures, net	2,694	2,657
Land	5,724	8,240
Construction in progress	85	2,518
Others	1,635	1,619
Accumulated depreciation	(126)	(192)
Others, net	1,509	1,426
Total Property, plant and equipment	24,213	28,835
Intangible assets		
Goodwill	7,006	6,645
Other	4,348	3,627
Total intangible assets	11,355	10,273
Investments and other assets		
Investments and other assets	1,053	1,363
Total investments and other assets	1,053	1,363
Total non-current assets	36,622	40,472
Total assets	75,009	77,343

The original disclosure in Japanese was released on November 10, 2020 at 15:00 (GMT+8)

(Millions of yen)

	As of Mar. 31, 2020	As of Sep. 30, 2020
Liabilities		
Current liabilities		
Notes and accounts payable-trade	1,027	1,366
Accrued income taxes	683	1,024
Provision	557	605
Other	3,978	5,000
Total current liabilities	6,248	7,996
Non-current liabilities		
Retirement benefit liabilities	783	775
Other	1,386	1,334
Total non-current liabilities	2,169	2,110
Total liabilities	8,418	10,106
Net assets		
Shareholders' equity		
Share capital	14,965	14,965
Capital surplus	32,893	32,893
Retained earnings	18,501	19,812
Total shareholders' equity	66,360	67,672
Accumulated other comprehensive income		
Foreign currency translation adjustment	436	(256)
Remeasurements of retirement benefit	(300)	(283)
Total accumulated other comprehensive income	135	(540)
Non-controlling interests	95	104
Total net assets	66,591	67,236
Total liabilities and net assets	75,009	77,343

The original disclosure in Japanese was released on November 10, 2020 at 15:00 (GMT+8)

(2) Consolidated Quarterly Statements of Profit or Loss and Consolidated Quarterly Statements of Comprehensive Income
(Consolidated Quarterly Statements of Profit or Loss)

(For the six months ended September 30, 2020)

(Millions of yen)

	Six months ended Sep. 30, 2019	Six months ended Sep. 30, 2020
Net sales	16,450	17,393
Cost of sales	6,121	5,565
Gross profit	10,329	11,827
SG&A expenses		
Employees' salaries and bonuses	1,957	2,082
Retirement benefit expenses	89	98
R&D expenses	1,858	2,403
Provision for doubtful accounts and bonuses	267	291
Other	3,121	3,214
Total SG&A expenses	7,293	8,090
Operating profit	3,035	3,736
Non-operating profit		
Interest income	59	60
Foreign exchange gains	—	2
Rent income from real estate	53	61
Other	17	18
Total non-operating profit	130	143
Non-operating expenses		
Interest expenses	—	12
Foreign exchange loss	176	—
Rent expenses on real estate	17	24
Expenses of inactive non-current assets	1	19
Other	8	3
Total non-operating expenses	203	59
Ordinary profit	2,961	3,820
Extraordinary profit		
Gain on sale of fixed assets	0	1
Total extraordinary profit	0	1
Extraordinary losses		
Loss on sale and retirement of fixed assets	9	25
Loss on business liquidation	—	464
Loss on sale of investment securities	2	—
Other	—	49
Total extraordinary losses	12	539
Profit before income taxes and others	2,950	3,281
Income taxes-current	665	1,203
Income taxes-deferred	205	(212)
Total income taxes	870	990
Net income	2,080	2,291
Net income attributable to non-controlling interest	4	16
Net income attributable to owners of the parent	2,075	2,274

The original disclosure in Japanese was released on November 10, 2020 at 15:00 (GMT+8)

(Consolidated Quarterly Statements of Comprehensive Income)

(For the six months ended September 30, 2020)

(Millions of yen)

	Six months ended Sep. 30, 2019	Six months ended Sep. 30, 2020
Net income	2,080	2,291
Other comprehensive income		
Foreign currency translation adjustment	(909)	(699)
Remeasurements of retirement benefit	12	16
Total other comprehensive income	(897)	(683)
Comprehensive income	1,182	1,608
Comprehensive income attributable to:		
Owners of the parent	1,179	1,598
Non-controlling interest	3	9

The original disclosure in Japanese was released on November 10, 2020 at 15:00 (GMT+8)

(3) Consolidated Quarterly Statements of Cash Flows

(Millions of yen)

	Six months ended Sep. 30, 2019	Six months ended Sep. 30, 2020
Net cash provided by (used in) operating activities		
Profit before income taxes and others	2,950	3,281
Depreciation and amortization	1,352	1,631
Depreciation and amortization on other	65	42
Amortization of goodwill	250	246
Increase (decrease) in allowance for doubtful accounts	0	1
Increase (decrease) in other provision	(39)	52
Increase (decrease) in retirement benefit liabilities	27	(7)
Interest income	(59)	(60)
Interest expenses	—	12
Loss (gain) on sale and retirement of fixed assets	9	24
Loss on business liquidation	—	464
Decrease (increase) in trade receivable-trade	2,903	572
Decrease (increase) in inventories	(546)	(1,481)
Increase (decrease) in notes and accounts payable-trade	(500)	374
Increase (decrease) in other current liabilities	(1,239)	1,178
Other	88	(14)
Subtotal	5,261	6,318
Interest and dividend income received	63	70
Income expenses paid	—	(12)
Income taxes paid	(615)	(822)
Net cash provided by (used in) operating activities	4,709	5,553
Net cash provided by (used in) investing activities		
Payments into time deposits	(2,049)	(1,657)
Proceeds from withdrawal of time deposits	2,100	3,122
Purchase of marketable securities	(2,000)	—
Proceeds from sale and redemption of marketable securities	2,000	2,000
Purchase of property, plant and equipment and intangible assets	(2,387)	(5,750)
Proceeds from sales of property, plant and equipment and intangible assets	100	14
Purchase of other depreciable assets	(47)	(141)
Other	0	(4)
Net cash provided by (used in) investing activities	(2,283)	(2,417)
Net cash provided by (used in) financing activities		
Dividends paid	(841)	(961)
Repayments of lease obligations	(43)	(68)
Net cash provided by (used in) financing activities	(884)	(1,030)
Effect of exchange rate change on cash and cash equivalents	(329)	(209)
Net increase (decrease) in cash and cash equivalents	1,212	1,897
Cash and cash equivalents at beginning of period	9,464	14,462
Cash and cash equivalents at end of period	10,676	16,360

The original disclosure in Japanese was released on November 10, 2020 at 15:00 (GMT+8)

(4) Notes to Consolidated Quarterly Financial Statements

(Notes on Premise of Going Concern)

No items to report.

(Notes in case of Changes in Marked Amount of Shareholders' Equity)

No items to report

(Additional Information)

(Accounting Estimates for the COVID-19 Pandemic)

At the end of the previous fiscal year, it was assumed that the impact of the COVID-19 on our group would continue during the first half of FY2021, albeit gradually recovering. However, based on information available at the time of preparation of the consolidated financial statements for the second quarter of the fiscal year under review, the Company revised the assumption that the impact will continue for a certain period of FY2022, although it varies by region. The Company made estimates and judgments regarding the impairment loss of goodwill and the recoverability of deferred tax assets at the end of the second quarter of the fiscal year under review based on revised assumptions, but no indicators of impairment have been identified for goodwill, and the Company has determined that no additional valuation allowance is required for the recoverability of deferred tax funds.

Due to the high degree of uncertainty associated with the impact of the COVID-19, any change in the above assumptions could have an impact on the Group's financial condition and results of operations.

(Segment Information)

【Segment Information】

I Equivalent period of previous fiscal year (From Apr. 1, 2019 to Sep. 30, 2019)

It is described in II the six months ended September 30, 2020 (Matters related to changes and others by reportable segment).

II Six months ended September 30, 2020 (From Apr. 1, 2020 to Sep. 30, 2020)

This information is omitted because the Company consists of a single segment.

(Matters related to changes and others by reportable segment)

The Company has established business divisions for each product and service, and each business division has formulated a comprehensive strategy for the products and services it handles, including its subsidiaries, and developed its business activities. In April 2020, however, we decided to dissolve a business division structures with the aim of becoming a drug discovery company that creates new modalities by integrating the management resources that each business division had and advancing the development of bio-drug discovery platform technologies.

As a result of this organizational review, the Bioindustry and Gene Therapy business segments, which were previously reported segments, have been changed to a single business segment from the first quarter of the fiscal year under review, and as a result, the reportable segments have become a single segment.

Due to this change, segment information for the second quarter of the previous fiscal year and the second quarter of the current fiscal year has been omitted.

The original disclosure in Japanese was released on November 10, 2020 at 15:00 (GMT+8)

3. Supplementary Information

(1) Trends in Key Management Indicators

1). Cash Flow

(Millions of yen)

Term	Six months ended Sep. 30, 2019 (Apr. 1, 2019 – Sep. 30, 2019)	Six months ended Sep. 30, 2020 (Apr. 1, 2020 - Sep. 30, 2020)	Year ended Mar. 31, 2020 (Apr. 1, 2019 - Mar. 31, 2020)
Net cash provided by (used in) operating activities	4,709	5,553	6,339
Net cash provided by (used in) investing activities	(2,283)	(2,417)	(212)
Net cash provided by (used in) financing activities	(884)	(1,030)	(946)

2). Net Sales by Region

(Millions of yen)

	Six months ended Sep. 30, 2019 (Apr. 1, 2019 – Sep. 30, 2019)	Six months ended Sep. 30, 2020 (Apr. 1, 2020 - Sep. 30, 2020)	Year ended Mar. 31, 2020 (Apr. 1, 2019 - Mar. 31, 2020)
Japan	6,816	6,906	14,804
U.S.	3,954	3,634	8,011
China	3,023	3,449	6,391
Asia excluding Japan and China	918	1,394	1,877
Europe	1,596	1,678	3,207
Other	141	330	271
Total	16,450	17,393	34,565

3). R&D expenses by reportable segment

Disclosure is omitted because the reportable segments have been changed to a single segment from the first quarter of the current fiscal year.

The original disclosure in Japanese was released on November 10, 2020 at 15:00 (GMT+8)

(2) Comparative Consolidated Statement of Profit

(Rounded down to one million yen)

	Six months ended Sep. 30, 2019 Actual	Six months ended Sep. 30, 2020 Actual	Year on year Change	Year on year Ratio
(Net Sales)				
Research reagents	11,824	13,336	1,512	112.8%
Scientific instruments	620	466	(153)	75.3%
Contract services	1,961	3,373	1,411	172.0%
Gene therapy	2,044	215	(1,828)	10.6%
Total net sales	16,450	17,393	942	105.7%
(Operating profit and Loss)				
Net sales	16,450	17,393	942	105.7%
Cost of sales	6,121	5,565	(555)	90.9%
Gross profits	10,329	11,827	1,498	114.5%
SG&A expenses	7,293	8,090	797	110.9%
Transportation expenses	186	336	149	180.5%
Advertising expenses	33	31	(2)	92.4%
Promotion expenses	299	276	(23)	92.3%
R&D expenses	1,858	2,403	544	129.3%
Administrative expenses, other	4,766	4,883	116	102.4%
Enterprise taxes (external standards taxation)	149	160	11	108.0%
Operating profit	3,035	3,736	701	123.1%
(Non-operating profit and Expenses)				
Non-operating profit	130	143	12	109.8%
Non-operating expenses	203	59	(144)	29.3%
Ordinary profit	2,961	3,820	858	129.0%
(Extraordinary profit & Losses)				
Extraordinary profit	0	1	0	251.6%
Extraordinary losses	12	539	527	4440.5%
Profit before income taxes and others	2,950	3,281	331	111.2%
Income taxes	870	990	120	113.8%
Net Income	2,080	2,291	211	110.2%
Net income (loss) attributable to non-controlling interests	4	16	12	358.5%
Net income attributable to owners of the parent	2,075	2,274	199	109.6%
Depreciation and amortization (Property, plant and equipment and intangible assets)	1,352	1,631	279	120.7%
Amortization of goodwill	250	246	(4)	98.4%

※1 Sales of “Other” in the previous fiscal year were included in “Research reagents” from the first quarter of current fiscal year, and results for the second quarter of the previous fiscal year in this table have been reclassified to reflect this change.

※2 The disclosure of profit and loss by segment (operating profit) is omitted because the reporting segments were changed to a single segment from the first quarter of the current fiscal year.

The original disclosure in Japanese was released on November 10, 2020 at 15:00 (GMT+8)

(3) Comparative Statement of Profit Relating to Consolidated Earnings Forecasts

(Rounded down to one million yen)

	Year ended Mar. 31, 2020 Actual	Year ending Mar. 31, 2021 Previous forecast	Year ending Mar. 31, 2021 Current forecast	Year on year Change	Year on year Ratio	Previous forecast Change	Previous forecast Ratio
(Net Sales)	(Net Sales)						
Research reagents	24,840	27,603	29,940	5,100	120.5%	2,337	108.5%
Scientific instruments	1,242	1,227	1,454	211	117.0%	226	118.5%
Contract services	6,186	9,850	8,539	2,352	138.0%	(1,310)	86.7%
Gene therapy	2,295	918	865	(1,430)	37.7%	(53)	94.2%
Total Net Sales	34,565	39,600	40,800	6,234	118.0%	1,200	103.0%
(Operating profit and Loss)							
Net Sales	34,565	39,600	40,800	6,234	118.0%	1,200	103.0%
Cost of sales	13,459	16,223	15,420	1,961	114.6%	(802)	95.1%
Gross profits	21,105	23,376	25,379	4,273	120.2%	2,002	108.6%
SG&A expenses	14,830	16,876	17,379	2,548	117.2%	502	103.0%
Transportation expenses	492	665	693	200	140.7%	27	104.2%
Advertising expenses	73	70	58	(14)	80.5%	(11)	84.0%
Promotion expenses	579	550	724	145	125.0%	174	131.7%
R&D expenses	3,869	5,121	5,173	1,303	133.7%	51	101.0%
Administrative expenses, other	9,511	10,157	10,399	888	109.3%	242	102.4%
Enterprise taxes (external standards taxation)	305	311	329	24	108.0%	17	105.8%
Operating profit	6,274	6,500	8,000	1,725	127.5%	1,500	123.1%
(Non-operating profit and Expenses)							
Non-operating profit	316	293	307	(8)	97.2%	14	105.0%
Non-operating expenses	243	193	207	(35)	85.3%	14	107.6%
Ordinary profit	6,347	6,600	8,100	1,752	127.6%	1,500	122.7%
(Extraordinary profit & Losses)							
Extraordinary profit	0	—	1	0	255.5%	1	—
Extraordinary losses	914	627	679	(235)	74.3%	51	108.2%
Profit before income taxes and others	5,433	5,972	7,421	1,988	136.6%	1,449	124.3%
Income taxes	1,601	1,961	2,394	792	149.5%	433	122.1%
Net Income	3,831	4,010	5,027	1,195	131.2%	1,016	125.3%
Net income (loss) attributable to non-controlling interests	11	10	27	15	227.3%	16	248.7%
Net income attributable to owners of the parent	3,819	4,000	5,000	1,180	130.9%	1,000	125.0%
Depreciation and amortization (Property, Plant and equipment and intangible assets)	2,921	3,268	3,305	383	113.1%	36	101.1%
Amortization of goodwill	496	486	486	(9)	98.0%	0	100.1%

※1 Sales of “Other” in the previous fiscal year were included in “Research reagents” from the current consolidated fiscal year, and results for equivalent period of previous fiscal year in this table have been reclassified to reflect these changes.

※2 The disclosure of profit and loss by segment (operating profit) is omitted because the reporting segments were changed to a single segment from the current consolidated fiscal year.